Log in

Relevant bibliographies by topics / 005. 32: 316. 46 (043.2)

Contents

Journal articles

Academic literature on the topic '005. 32: 316. 46 (043.2)'

Author: Grafiati

Published: 30 May 2022

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic '005. 32: 316. 46 (043.2).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "005. 32: 316. 46 (043.2)"

1

Karkash, Ahmad, Weston He, Paresh Kumar, Mya Tran, Julian A. Marin-Acevedo, and Misty Dawn Shields. "Comparison of outcomes for patients diagnosed with small cell lung cancer between a university and safety net hospital." Journal of Clinical Oncology 43, no. 16_suppl (2025): 12077. https://doi.org/10.1200/jco.2025.43.16_suppl.12077.

Full text

Abstract:

12077 Background: With immunotherapy, the five year overall survival (OS) for small cell lung cancer (SCLC) is 12%. However, real world factors such as social determinants of health (SDH) and enrollment to clinical trials may vary. Here, we compare treatment patterns and outcomes for SCLC between two affiliated hospital settings. Methods: A retrospective analysis was conducted on patients with SCLC seen at university hospital (UH, Indiana University Melvin and Bren Simon Comprehensive Cancer Center) or its affiliate safety net hospital (SNH, Sidney and Lois Eskenazi Hospital) from 1/1/2018 to

APA, Harvard, Vancouver, ISO, and other styles

2

Yoh, Kyung Ah, Ho Sup Lee, Lee Chun Park, Eun Mi Lee, Dae Jin Park, and Yang Soo Kim. "Prognostic Significance of Elevated Serum Ferritin Before Chemotherapy in Patients with Non-Hodgkin's Lymphoma." Blood 120, no. 21 (2012): 5099. http://dx.doi.org/10.1182/blood.v120.21.5099.5099.

Full text

Abstract:

Abstract Abstract 5099 Background: Elevated ferritin level before stem cell transplantation was documented an adverse prognostic factor for patients undergoing hematopoietic stem cell transplantation for hematologic malignancies. Until now, there have been reported few studies which suggested high serum ferritin level were associated with worse outcomes for lymphoma. The purpose of this study was to find the significance of high levels of serum ferritin for predicting survival outcome in patients with non-Hodgkin's lymphoma (NHL). Methods: A total of 267 patients who newly diagnosed and receiv

APA, Harvard, Vancouver, ISO, and other styles

3

Gerasimova, E., T. Popkova, A. Aleksankin, and D. Tabakov. "POS0622 THE BLOOD T-CELL SUBSETS IN RHEUMATOID ARTHRITIS PATIENTS ON LONG-TERM IL-6 RECEPTOR BLOCKER THERAPY." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 549.1–549. http://dx.doi.org/10.1136/annrheumdis-2021-eular.2310.

Full text

Abstract:

Background:Pleiotropic effects of IL-6 receptor antagonist tocilizumab (TCZ) in rheumatoid arthritis (RA) involve circulating T-cells. Preliminary reports have suggested that TCZ therapy can modulate T cell function and humoral immune responses in RA [1,2]. According to other studies, TCZ had no influence on T-lymphocyte subdifferentiation [3].Objectives:To assess the effect of 12 months (m) TCZ therapy on T-cell phenotype, and to analyze the association between T-cell subsets and RA activity.Methods:36 active RA pts (29F/7M); median age 55[46; 64] years; disease duration 120[72; 1928]m; DAS28

APA, Harvard, Vancouver, ISO, and other styles

4

Zhu, Katie Y., Kevin W. Song, Joseph M. Connors, et al. "Population-Based Survival Outcomes in Adult Patients with Burkitt Lymphoma (BL) Treated with Cyclophosphamide, Vincristine, Doxorubicin, High-Dose Methotrexate (CODOX-M)/Ifosfamide, Etoposide and High-Dose Cytarabine (IVAC) Plus or Minus Rituximab (R) in British Columbia (BC), Canada." Blood 128, no. 22 (2016): 1113. http://dx.doi.org/10.1182/blood.v128.22.1113.1113.

Full text

Abstract:

Abstract Background: Burkitt lymphoma (BL) is a highly aggressive non-Hodgkin lymphoma associated with translocations involving the c-MYC oncogene on chromosome 8. The 1996 Magrath regimen, CODOX-M/IVAC, showed a promising 2-year (y) event free survival (EFS) of 92% in 41 BL patients (pts), with additional trials of a dose-modified regimen demonstrating 2y overall survival (OS) 70-82% and 2y progression-free survival (PFS) 64% (Mead et al). A recent trial demonstrated that with addition of R, 3y OS and EFS were 83% and 75% (Ribrag et al). We sought to determine survival outcomes of adult BL pt

APA, Harvard, Vancouver, ISO, and other styles

5

Bowmaker, Graham A., Peter C. Junk, Aaron M. Lee, Brian W. Skelton, and Allan H. White. "Synthetic, Structural and Vibrational Spectroscopic Studies in Bismuth(III) Halide/N,N′-Aromatic Bidentate Base Systems. I Large-Cation (2,2′-Bipyridinium and 1,10-Phenan- throlinium) Salts of Polyhalobismuthate(III) Ions." Australian Journal of Chemistry 51, no. 4 (1998): 293. http://dx.doi.org/10.1071/c97036.

Full text

Abstract:

Syntheses and room-temperature single-crystal X-ray studies are recorded for a variety of salts of cations derived from protonated 2,2′-bipyridine and 1,10-phenanthroline (bpyH+ and phenH+) with polyhalobismuthate(III) anions. ‘[(phenH)(phenH2)(H2O)2] [BiCl6]’ is triclinic, P-1, a 9·791(1), b 9·338(3), c 8·311(3) Å, α 73·46(3), β 69·71(2), γ 86·36(2)°, Z = 1; conventional R on |F| was 0·027 for No 4852 independent ‘observed’ (I > 3σ(I)) reflections. [BiCl6]3- is closely octahedral, accompanied by an interesting protonation/hydrogen-bonding array among the other moieties. The latter comment

APA, Harvard, Vancouver, ISO, and other styles

6

Flouri, I., A. Repa, N. Avgustidis, et al. "AB0375 IN PATIENTS STARTING ETANERCEPT, MALE SEX, ABSENCE OF COMORBIDITIES AND NO csDMARDs CO-ADMINISTRATION ARE INDEPENDENT PREDICTORS OF LONG-TERM (MORE THAN 3 YEARS) PERSISTENCE TO THERAPY, IRRESPECTIVELY OF THE CLINICAL DIAGNOSIS." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 1314.2–1315. http://dx.doi.org/10.1136/annrheumdis-2022-eular.4826.

Full text

Abstract:

BackgroundComparative data among rheumatoid arthritis (RA), spondylarthritis (SpA) and psoriatic arthritis (PsA) patients regarding long-term survival of etanercept (ETN) in clinical practice are limited.ObjectivesThe first aim of this study was to analyze the long-term (>3 years) ETN survival comparatively between its three main indications. We also aimed to analyze for predictors of long term ETN survival.MethodsWe analyzed data from the University of Crete Rheumatology Clinic Registry (UCRCR), a single center prospective cohort study. All patients with a diagnosis of RA, SpA or PsA start

APA, Harvard, Vancouver, ISO, and other styles

7

Wenzel, Mike, Florestan Koll, Benedikt Hoeh, et al. "Cancer-control outcomes of metastatic castration resistant prostate cancer patients with BRCA -gene or tumor suppressor mutations undergoing 177-lutetium PSMA radioligand therapy." Journal of Clinical Oncology 43, no. 5_suppl (2025): 71. https://doi.org/10.1200/jco.2025.43.5_suppl.71.

Full text

Abstract:

71 Background: Several tumor gene mutations are known for metastatic castration-resistant prostate cancer (mCRPC) are known. The individual response to 177-Lutetium Prostate-specific membrane antigen (Lu-PSMA) therapy is under current investigation regarding the genomic profile of mCRPC patients. Methods: We relied on the FRAMCAP database and compared progression-free (PFS) and overall survival (OS) rates of mCRPC patients with Breast Cancer related antigen ( BRCA ) or tumor suppressor gene mutations ( TP53, PTEN, RB1 [TSG]). Especially, subgroup analyses were performed for Lu-PSMA-treated mCR

APA, Harvard, Vancouver, ISO, and other styles

8

Suzuki, Gen, Brian R. Weil, Rebeccah F. Young, James A. Fallavollita, and John M. Canty. "Nonocclusive multivessel intracoronary infusion of allogeneic cardiosphere-derived cells early after reperfusion prevents remote zone myocyte loss and improves global left ventricular function in swine with myocardial infarction." American Journal of Physiology-Heart and Circulatory Physiology 317, no. 2 (2019): H345—H356. http://dx.doi.org/10.1152/ajpheart.00124.2019.

Full text

Abstract:

Intracoronary cardiosphere-derived cells (icCDCs) infused into the infarct-related artery reduce scar volume but do not improve left ventricular (LV) ejection fraction (LVEF). We tested the hypothesis that this reflects the inability of regional delivery to prevent myocyte death or promote myocyte proliferation in viable myocardium remote from the infarct. Swine ( n = 23) pretreated with oral cyclosporine (200 mg/day) underwent a 1-h left anterior descending coronary artery (LAD) occlusion, which reduced LVEF from 61.6 ± 1.0 to 45.3 ± 1.5% 30 min after reperfusion. At that time, animals receiv

APA, Harvard, Vancouver, ISO, and other styles

9

Gamboa-Alonso, C. M., M. J. Garza Martínez, B. R. Vázquez Fuentes, et al. "SAT0206 MINOR SALIVARY GLAND BIOPSY AND SEROLOGICAL PROFILE IN PRIMARY SJÖGREN’S SYNDROME: A SINGLE TERTIARY REFERRAL CENTER EXPERIENCE." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 1046.2–1046. http://dx.doi.org/10.1136/annrheumdis-2020-eular.6278.

Full text

Abstract:

Background:Minor salivary gland biopsy (MSGB) portrays an important role as part of the diagnostic criteria of primary Sjögren’s syndrome (pSS) in the ACR/EULAR 2016 classification. Autoantibodies anti-Ro/SSA and anti-La/SSB embody part of these criteria. Patients with negative serology have been classified as pSS using MSGB outcomes in up to 40% of cases.Objectives:Compare MSGB and serological characteristics between pSS positive biopsy versus pSS negative biopsy and sicca groups.Methods:174 subjects with sicca symptoms and MSGB biopsy were studied. Patients who fulfilled the ACR/EULAR 2016 c

APA, Harvard, Vancouver, ISO, and other styles

10

Deodhar, A., S. Kafka, E. C. Hsia, et al. "POS0902 EFFICACY AND SAFETY OF INTRAVENOUS GOLIMUMAB IN ANKYLOSING SPONDYLITIS PATIENTS WITH EARLY VS LATE DISEASE THROUGH WEEK 52 OF GO-ALIVE STUDY." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 708–9. http://dx.doi.org/10.1136/annrheumdis-2021-eular.220.

Full text

Abstract:

Background:The GO-ALIVE study assessed efficacy and safety of intravenous golimumab (IV GLM) in patients (pts) with ankylosing spondylitis (AS).1,2Objectives:In this post hoc analysis, we assessed IV GLM efficacy and safety in AS pts with early disease (ED) vs late disease (LD) based on pt-reported duration of inflammatory back pain (IBP).Methods:In this Phase 3, double-blind, placebo (PBO)-controlled trial, pts with active AS were randomized (1:1) to receive IV GLM 2 mg/kg at Week (W) 0, W4, then Q8W or PBO at W0, W4, and W12 with crossover to IV GLM at W16, W20, then Q8W through 52. The prim

APA, Harvard, Vancouver, ISO, and other styles

More sources

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!